Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer …
A Rossi, R Pasquale, C Esposito… - Cancer Treatment Reviews, 2013 - Elsevier
An ideal target-based agent for the treatment of cancer patients should fulfil a number of
requirements, including the availability of biomarkers to select the target population …
requirements, including the availability of biomarkers to select the target population …
First-line epidermal growth factor receptor (EGFR) kinase inhibitors for EGFR mutant non-small cell lung cancer: And the winner is…
O Juan, N Yousaf, S Popat - Clinical Oncology, 2017 - clinicaloncologyonline.net
Sensitising mutations of the epidermal growth factor receptor (EGFR) tyrosine kinase
domain have been described in up to 17% of Caucasian patients with lung cancer, mostly …
domain have been described in up to 17% of Caucasian patients with lung cancer, mostly …
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR
S Mitsuoka, T Kawaguchi, A Kubo, S Isa… - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: While epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors
(TKIs) lead to longer progression-free survival (PFS) when compared with conventional …
(TKIs) lead to longer progression-free survival (PFS) when compared with conventional …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
Clinical activity of ASP 8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations
H Murakami, H Nokihara, H Hayashi, T Seto… - Cancer …, 2018 - Wiley Online Library
Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine
kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP 8273 is a …
kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP 8273 is a …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR …
JL Kuiper, DAM Heideman, T Würdinger, K Grünberg… - Clinical lung cancer, 2015 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
shown improved progression-free survival (PFS) and overall survival (OS) over …
shown improved progression-free survival (PFS) and overall survival (OS) over …
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status
Y Okuma, Y Hosomi, M Nagamata… - Anticancer …, 2013 - ar.iiarjournals.org
Background: The phase II NEJ001 trial suggested that gefitinib was active against advanced
non-small cell lung cancer (NSCLC) even in patients with poor performance status (PS) …
non-small cell lung cancer (NSCLC) even in patients with poor performance status (PS) …
Efficacy of tyrosine kinase inhibitors in non‑small‑cell lung cancer patients undergoing dose reduction and those with a low body surface area
S Sato, K Kurishima, K Miyazaki… - Molecular and …, 2014 - spandidos-publications.com
The objective of this study was to evaluate the efficacy of epidermal growth factor receptor‑
tyrosine kinase inhibitors (EGFR‑TKIs) in patients undergoing dose reduction and in those …
tyrosine kinase inhibitors (EGFR‑TKIs) in patients undergoing dose reduction and in those …
[HTML][HTML] Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation
T Fukuhara, M Maemondo, A Inoue, K Kobayashi… - Lung Cancer, 2015 - Elsevier
Introduction Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)
treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR …
treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR …